We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Sequencing-Based Technology to Deliver ‘Holy Grail’ of Infectious Disease Diagnostics

By LabMedica International staff writers
Posted on 25 Sep 2023
Print article
Image: The Blood2Bac process enables high-depth, whole-genome sequence coverage of bacterial pathogens directly from clinical blood samples (Photo courtesy of Day Zero Diagnostics)
Image: The Blood2Bac process enables high-depth, whole-genome sequence coverage of bacterial pathogens directly from clinical blood samples (Photo courtesy of Day Zero Diagnostics)

Antimicrobial resistance is a growing global problem that encompasses not just bacterial resistance to antibiotics but also fungal resistance. The overuse of antibiotics has resulted in pathogens becoming resistant to formerly effective medications at a rate that outstrips the creation of new drugs. Treating antibiotic-resistant infections is not only more difficult and costly, but it also typically entails longer hospital stays, extra follow-up consultations, and more expensive, toxic alternative therapies. Such drug-resistant bacteria are increasingly leading to fatal outcomes, particularly in severe infections like sepsis. While timely and appropriate treatment can save lives, existing technologies often don't yield fast enough results for immediate, targeted antibiotic treatment. Moreover, cultures fail to grow in as many as half of all serious bloodstream infections.

Day Zero Diagnostics (Boston, MA, USA) is pioneering a new class of infectious disease diagnostics using the power of whole-genome sequencing and artificial intelligence (AI) to combat the rise of antibiotic-resistant infections. The company is developing a sequencing-based diagnostic that can identify a broad array of bacterial and fungal pathogens while also determining their susceptibility to antimicrobials, all in under eight hours. This is a significant improvement over current methods, which can take days and are associated with an 8% increase in mortality rate for each passing hour.

The company is completing the development of an enhanced Blood2Bac sample preparation protocol that requires smaller sample sizes and is more cost-effective. This protocol is capable of capturing both fungi and bacteria. Day Zero Diagnostics is also fast-tracking the development of a commercial prototype system, incorporating both the hardware and a cloud-based AI algorithm suite called Keynome, which ensures highly accurate identification of organisms and their antimicrobial susceptibility. Hospitals adopting this diagnostic approach can expect reduced lengths of patient stays, minimized use of costly and toxic antibiotics that might not be effective, and most crucially, saved lives.

"DZD is focused on bringing an FDA-cleared diagnostic to market that will deliver the 'holy grail' of infectious disease diagnostics – same day organism identification and antimicrobial susceptibility profiling directly from clinical samples, and our investors share our belief in the game changing nature of our technology," said Jong Lee, CEO and co-founder of Day Zero Diagnostics.

Related Links:
Day Zero Diagnostics

Platinum Supplier
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Gold Supplier
Blood Glucose Reference Analyzer
Nova Primary
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Myoglobin Emergency Marker
PATHFAST Myo

Print article

Channels

Clinical Chemistry

view channel
Image: A module with eight micro-devices, complete with microfluidic channels and drive motors (Photo courtesy of U.S Department of Energy)

Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses

Understanding the acidity or alkalinity of substances through pH measurement is crucial in many fields, from environmental monitoring to healthcare product safety. In many cases, these measurements must... Read more

Molecular Diagnostics

view channel
Image: Scientists have discovered a new amyloid-forming protein in neurodegenerative disease (Photo courtesy of 123RF)

Discovery of Rogue Protein Paves Way for Diagnostic Test to Detect Early-Onset Dementia

Neurodegenerative disorders are often marked by the buildup of amyloid filament inclusions of specific proteins in the brain. These proteins are critical in diagnosing and treating the associated diseases.... Read more

Hematology

view channel
Image: The QScout hematology analyzer has received US FDA 510(k) clearance (Photo courtesy of Ad Astra Diagnostics)

First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC

Sepsis, a critical medical condition that arises as an extreme response to infection, poses a significant health threat. It occurs when an infection triggers a widespread inflammatory response in the body.... Read more

Immunology

view channel
Image: PointCheck is the world’s first device for non-invasive white cell monitoring (Photo courtesy of Leuko Labs)

World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw

One of the toughest challenges for cancer patients undergoing chemotherapy is experiencing a low count of white blood cells, also known as neutropenia. These cells play a crucial role in warding off infections.... Read more

Technology

view channel
Image: Made-to-order diagnostic tests may soon be on the horizon (Photo courtesy of McGill University)

Breakthrough in Diagnostic Technology Could Make On-The-Spot Testing Widely Accessible

Home testing gained significant importance during the COVID-19 pandemic, yet the availability of rapid tests is limited, and most of them can only drive one liquid across the strip, leading to continued... Read more

Industry

view channel
Image: Covaris offers instruments, consumables, and reagents for high-throughput genomic and proteomic analysis (Photo courtesy of Covaris)

PerkinElmer Acquires Covaris to Create Global Life-Sciences and Diagnostics Platform

PerkinElmer, Inc. (Waltham, MA, USA), a global analytical services and solutions provider has acquired Covaris (Woburn, MA, USA), a developer of solutions to empower life science innovations.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.